"Loading Stock Price & Valuation Data ..."
Unlock News Summary by Subscribing to iPick.ai Premium!
Ask anything related to STTK. [ FAQ on what and how to ask] For non-STTK questions, click the logo in the upper-right corner to return to the main page and ask there.
CEO:Dr. Taylor H. Schreiber M.D., Ph.D.
Headquarter: 500 West 5th Street, Suite 1200, Austin, TX, United States, 78701
Industry: Biotechnology, Investment Track: -, Employees: 40
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.
My Watchlist
